Plasminogen activator inhibitor type-1 (Part two): Role for failure of thrombolytic therapy. PAI-1 resistance as a potential benefit for new fibrinolytic agents

Journal of Thrombosis and Thrombolysis

Volumn 11, Issue 3, 2001, Pages 195-202

  Huber, K ^a  

^a UNIVERSITY OF VIENNA   (Austria)

Author keywords

Fibrinolytic agents; PAI 1 resistance; Thrombolytic therapy; TNK t PA

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 BENZYLIDENE 4 (3,4,5 TRIMETHOXYBENZYLIDENE)SUCCINIMIDE; ACETYLSALICYLIC ACID; FIBRINOGEN; FIBRINOLYTIC AGENT; HEPARIN; LANOTEPLASE; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY CLB 2C8; MONOCLONAL ANTIBODY MAI 12; PLASMINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLASMINOGEN ACTIVATOR INHIBITOR 1 ANTIBODY; POLYCLONAL ANTIBODY; POLYCLONAL ANTIBODY PRAP 1; RETEPLASE; STAPHYLOKINASE; TENECTEPLASE; TISSUE PLASMINOGEN ACTIVATOR; UNCLASSIFIED DRUG; UROKINASE; XR 5118;

ACUTE HEART INFARCTION; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CORONARY ARTERY OBSTRUCTION; CORONARY REPERFUSION; DRUG APPROVAL; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EFFECT; DRUG EFFICACY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; FIBRINOLYSIS; FIBRINOLYTIC THERAPY; GENETIC ENGINEERING; HUMAN; IN VIVO STUDY; METABOLIC INHIBITION; MOLECULAR WEIGHT; MORTALITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN STRUCTURE; PROTEIN VARIANT; REVIEW; SITE DIRECTED MUTAGENESIS; THROMBOSIS; TREATMENT FAILURE;

ANIMALS; DRUG DESIGN; FIBRINOLYTIC AGENTS; HUMANS; MODELS, ANIMAL; MYOCARDIAL INFARCTION; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN ENGINEERING; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT FAILURE;

EID: 0035174817     PISSN: 09295305     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1011952602122     Document Type: Review

References (78)

1. Immediate vs delayed catheterization and angioplasty following thrombolytic therapy for acute myocardial infarction
2. The GUSTO Angiographic Investigators: The effects of tissue plasminogen activator, streptokinase, or both on coronary artery patency, ventricular function, and survival after myocardial infarction
3. Trickle down thrombolysis
4. Extended mortality benefit of early postinfarction reperfusion
5. The role of type-1 plasminogen activator inhibitor in failure of thrombolytic therapy with recombinant tissue plasminogen activator
6. Thrombolytic therapy in acute myocardial infarction
7. Elevated levels of the rapid inhibitor of plasminogen activator (t-PAI) in acute myocardial infarction
8. Correlation of baseline plasminogen activator inhibitor activity with patency of the infarct related artery after thrombolytic therapy in acute myocardial infarction
9. Correlation between baseline plasminogen activator inhibitor levels and clinical outcome during therapy with tissue plasminogen activator for acute myocardial infarction
10. The status of PAI-1 as a risk factor for arterial and thrombotic disease
11. Lysis of platelet-rich thrombi: The role of PAI-1
12. Enzymatic evidence of impaired reperfusion in diabetic patients after thrombolytic therapy for acute myocardial infarction: A role for plasminogen activator inhibitor?
13. Attenuation of thrombolysis by release of plasminogen activator inhibitor type-1 from platelets
14. Pretreatment plasminogen activator inhibitor-1 (PAI-1) levels and the outcome of thrombolysis with streptokinase in patients with acute myocardial infarction
15. Link between the angiographic sub-study and mortality outcomes in a large randomized trial of myocardial reperfusion: Importance of early and complete infarct artery reperfusion
16. Sixty-minute alteplase protocol: A new accelerated recombinant tissue-type plasminogen activator regimen for thrombolysis in acute myocardial infarction
17. Biochemical determinants of clearance of tissue-type plasminogen activator from the circulation
18. Dependence of fibrinolytic activity on the concentration of free rather than total tissue-type plasminogen activator in plasma after pharmacologic administration
19. Plasma levels of plasminogen activator inhibitor type 1, b-thrombomodulin, and fibrinopeptide A before, during, and after treatment of acute myocardial infarction with alteplase
20. Attenuation of thrombolysis-induced increase of plasminogen activator inhibitor-1 by intravenous enalaprilat
21. Rebound increase of plasminogen activator inhibitor type 1 after cessation of thrombolytic treatment for acute myocardial infarction is independent of type of plasminogen activator used
22. Circadian variation in thrombolytic response to recombinant tissue-type plasminogen activator in acute myocardial infarction
23. Circadian variation in the efficacy of tissue-type plasminogen activator
24. Circadian variations of onset of acute myocardial infarction and efficacy of thrombolytic therapy
25. Circadian variation in the success rate of intracoronary thrombolysis for acute myocardial infarction
26. Circadian variation in the frequency of onset of acute myocardial infarction
27. Major circadian fluctuations in fibrinolytic factors and possible relevance to time of onset of myocardial infarction, sudden cardiac death and stroke
28. Diurnal variation of tissue-type plasminogen activator and its rapid inhibitor (PAI-1)
29. Circadian variation of plasminogen activator inhibitor and tissue plasminogen activator levels in plasma of patients with unstable coronary artery disease and acute myocardial infarction
30. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death
31. Plasminogen activator inhibitor (PAI-1) in plasma and platelets
32. Induction of endothelial cell expression of the plasminogen activator inhibitor PAI-1 gene by thrombosis in vivo
33. Mechanisms contributing to increased synthesis of plasminogen activator inhibitor type 1 in endothelial cells by constituents of platelets and their implications for thrombosis
34. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries
35. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries
36. High concentrations of active plasminogen activator inhibitor-1 in porcine coronary arteries
37. Changes in arterial expression of fibrinolytic system proteins in atherogenesis
38. Plasminogen activator inhibitor-1 secretion of endothelial cells increases fibrinolytic resistance of an in vitro clot: Evidence for a key role of endothelial cells in thrombolytic resistance
39. Detailed localization of type-1 plasminogen activator inhibitor mRNA expression and antigen in atherosclerotic plaque on human coronary artery
40. Differential sensitivity of erythrocyte-rich and platelet-rich arterial thrombi to lysis with recombinant tissue-type plasminogen activator
41. Inhibition of plasminogen activator inhibitor-1 activity results in promotion of endogenous thrombolysis and inhibition of thrombus extension in models of experimental thrombosis
42. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in the thrombolysis resistance: Studies with thrombi generated in the Chandler loop
43. Suppression of thrombolysis in a canine model of pulmonary embolism
44. Regulation of arterial thrombolysis by plasminogen activator inhibitor-1 in mice
45. Plasminogen activator inhibitor-1 is a major determinant of arterial thrombolysis resistance
46. Common evolutionary origin of the fibrin-binding structures of fibronectin and tissue-type plasminogen activator
47. Cloning and expression of human tissue-type plasminogen activator cxDNA in E-Coli
48. Serpin-resistant mutants of human tissue-type plasminogen activator
49. Probing structure-function relationships of tissue-type plasminogen activator by site-specific mutagenesis
50. Site-directed mutagenesis of tissue-type plasminogen activator
51. Amino acid residues that affect interaction of tissue-type plasminogen activator with plasminogen activator inhibitor-1
52. High resolution analysis of functional determinants on human tissue-type plasminogen activator
53. A slow clearing, fibrin-specific PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA)
54. The 2.3 A crystal structure of the catalytic domain of recombinant two-chain human tissue-type plasminogen activator
55. A variant of tissue plasminogen activator (t103N, N117Q, KHRR 296-299 AAAA) with a decreased plasma clearance rate is substantially more potent than Activase TM rt-PA in a rabbit thrombolysis model
56. A faster-acting and more potent form of tissue plasminogen activator
57. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA
58. Electrical induction of coronary artery thrombosis in the ambulatory canine: A model for in vivo evaluation of anti-thrombotic agents
59. Pathologic basis of failure of concurrent glyceryl trinitrate therapy to improve efficacy of tissue-type plasminogen activator in coronary thrombosis
60. Sustained reflow in dogs with coronary thrombosis with K2P, a novel mutant of tissue-plasminogen activator
61. TNK-tissue plasminogen activator in acute myocardial infarction: Results of the thrombolysis in myocardial infarction (TIMI) 10A dose-ranging trial
62. Hemorrhagic events during therapy with recombinant tissue-type plasminogen activator, herparin, and aspirin for acute myocardial infarction
63. Comparison of front-loaded recombinant tissue-type plasminogen activator, anistreplase and combination thrombolytic therapy for acute myocardial infarction: Results of the Thrombolysis in Myocardial Infarction (TIMI) 4 trial
64. A randomized trial of recombinant staphylokinase versus alteplase for coronary artery patency in acute myocardial infarction
65. TNK-tissue plasminogen activator compared with front-loaded alteplase in acute myocardial infarction. Results of the TIMI 10B Trial
66. Safety assessment of TNK-tissue plasminogen activator in acute myocardial infarction: The ASSENT-1 Trial
67. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: The ASSENT-2 double-blind randomised trial. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators
68. Serial changes of plasminogen activator inhibitor activity in thrombolytic therapy for acute myocardial infarction. Comparison between thrombolytic therapies with mutant t-PA (lanoteplase/BMS-200980) and recombinant t-PA (alteplase)
69. Anti-thrombotic effect of a PAI-1 inhibitor in rats given endotoxin
70. The Fab-fragment of a PAI-1 inhibiting antibody reduces thrombus size and restores blood flow in a rat model of arterial thrombosis
71. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator-inhibitor type-1 neutralizing monoclonal antibody
72. Suppression of plasminogen activator inhibitor 1 (PAI-1) activity levels in rats by monoclonal antibodies
73. Novel low-molecular-weight inhibitor of PAI-1 (XR5118) promotes endogenous fibrinolysis and reduces post-thrombolysis thrombus growth in rabbits
74. Identification of the binding site for a low-molecular weight inhibitor of plasminogen activator inhibitor type 1 by site-directed mutagenesis
75. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARg in endothelial function
76. Sideroxylonal C, a new inhibitor of human plasminogen activator inhibitor type-1, from the flowers of Eucalyptus albens
77. T-686, a novel inhibitor of plasminogen activator inhibitor-1, inhibits thrombosis without impairment of hemaostasis in rats
78. A new butadiene derivative, T-686, inhibits plasminogen activator inhibitor type-1 production in vitro by cultured human vascular endothelial cells and development of atherosclerotic lesions in vivo in rabbits